NTRK1 and neoplasm: These agents have demonstrated good efficacy and tolerability across a wide range of NTRK fusion-positive malignancies and two TRK inhibitors are approved by the US Food and Drug Administration for use in patients with unresectable or metastatic NTRK fusion-positive cancers, agnostic of tumor type.